FDA Advisory Committee Recommends Approval for Cannabis Derived Treatment for Epilepsy

An FDA advisory committee voted unanimously to recommend approval of a drug for Lennox-Gastaut syndrome and Dravet syndrome that, if approved, would be the first FDA-approved cannabis-derived product, GW Pharma’s NDA for a cannabidiol oral solution.
Source: Drug Industry Daily